Dr. Pettaway on the Prevalence of Germline Mutations in Diverse Populations With Prostate Cancer

Video

In Partnership With:

Curtis A. Pettaway, MD, professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the prevalence of germline mutations in diverse populations with prostate cancer.

Curtis A. Pettaway, MD, professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the prevalence of germline mutations in diverse populations with prostate cancer.

Historically, germline mutations such as BRCA1/2 have not been well described in African American, Asian, and Hispanic communities, says Pettway. However, multigene molecular sequencing panels has made it easier to discover genetic alterations in these patient populations. Though rare, these alterations could have prognostic and therapeutic implications for patients and their families, says Pettaway.

As such, it is important to increase awareness regarding the prevalence of these mutations in racially diverse populations and increase access to testing platforms to ensure that these patients can receive optimal care, concludes Pettaway.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine